Overview
NICE is unable to make a recommendation about the use in the NHS of enzalutamide (Xtandi) for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. This is because Astellas Pharma did not provide an evidence submission.
Last reviewed: 08 August 2024
Next review: We will review this decision if the company decides to make a submission.